Understanding why treatments for juvenile idiopathic arthritis affect children differently has never been well understood – ...
Assessing patient suitability for the first-line combination of enfortumab vedotin and pembrolizumab in advanced urothelial cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback